CO2020016480A2 - Sales tópicas de amlodipino para el tratamiento de enfermedades anorrectales - Google Patents

Sales tópicas de amlodipino para el tratamiento de enfermedades anorrectales

Info

Publication number
CO2020016480A2
CO2020016480A2 CONC2020/0016480A CO2020016480A CO2020016480A2 CO 2020016480 A2 CO2020016480 A2 CO 2020016480A2 CO 2020016480 A CO2020016480 A CO 2020016480A CO 2020016480 A2 CO2020016480 A2 CO 2020016480A2
Authority
CO
Colombia
Prior art keywords
amlodipine
topical
salts
treatment
anorectal diseases
Prior art date
Application number
CONC2020/0016480A
Other languages
English (en)
Inventor
László Ritter
László Hornok
Péter Matyus
Romána Zelko
Andrea Ujhelyi
Richárd Karpati
Tamás Solymosi
Hristos Glavinas
Original Assignee
Tavanta Therapeutics Hungary Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tavanta Therapeutics Hungary Incorporated filed Critical Tavanta Therapeutics Hungary Incorporated
Publication of CO2020016480A2 publication Critical patent/CO2020016480A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

RESUMEN DE LA INVENCIÓN Se proporciona una composición farmacéutica tópica en gel de una sal de amlodipino y métodos para su uso en el tratamiento de enfermedad anorrectal.
CONC2020/0016480A 2018-06-01 2020-12-26 Sales tópicas de amlodipino para el tratamiento de enfermedades anorrectales CO2020016480A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862679137P 2018-06-01 2018-06-01
US201962822400P 2019-03-22 2019-03-22
PCT/IB2019/000689 WO2019229535A2 (en) 2018-06-01 2019-05-29 Topical amlodipine salts for the treatment of anorectal diseases

Publications (1)

Publication Number Publication Date
CO2020016480A2 true CO2020016480A2 (es) 2021-03-19

Family

ID=67928855

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0016480A CO2020016480A2 (es) 2018-06-01 2020-12-26 Sales tópicas de amlodipino para el tratamiento de enfermedades anorrectales

Country Status (14)

Country Link
US (3) US11197848B2 (es)
EP (1) EP3801460A2 (es)
JP (1) JP2021526554A (es)
KR (1) KR20210023908A (es)
CN (1) CN112423736A (es)
AU (1) AU2019276832A1 (es)
BR (1) BR112020024395A2 (es)
CA (1) CA3102228A1 (es)
CO (1) CO2020016480A2 (es)
CR (1) CR20200630A (es)
IL (1) IL279121B1 (es)
MX (1) MX2020012949A (es)
SG (1) SG11202012365QA (es)
WO (1) WO2019229535A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11197848B2 (en) 2018-06-01 2021-12-14 Tavanta Therapeutics Hungary Incorporated Topical amlodipine salts for the treatment of anorectal diseases
US11253474B1 (en) 2021-02-01 2022-02-22 Liqmeds Worldwide Limited Pharmaceutical solution of amlodipine

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1331137C (en) * 1988-02-29 1994-08-02 Pfizer, Inc. Transdermal flux enhancing compositions
WO1995006466A1 (en) 1993-09-01 1995-03-09 Koren Laboratories Pty. Limited Treatment of anorectal disorders
US8048875B1 (en) 1997-02-24 2011-11-01 S.L.A. Pharma Ag Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
CN1127333C (zh) 1997-02-24 2003-11-12 S.L.A.药业股份公司 含有胆碱能药物或钙通道阻滞剂的局部用医药组合物
AU6767198A (en) * 1998-03-26 1999-05-03 Dr. Reddy's Laboratories Limited Stable pharmaceutical composition containing amlodipine besylate and atenol ol
AU764921B2 (en) * 1998-12-14 2003-09-04 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
US6391869B1 (en) 1998-12-14 2002-05-21 Cellergy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
IL129102A0 (en) * 1999-03-22 2000-02-17 J P M E D Ltd An emulsion
IL137275A0 (en) 2000-07-12 2001-07-24 Yosefus Azaria Pharmaceutical composition for the treatment of anal fissures
US8425892B2 (en) 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
WO2003075851A2 (en) 2002-03-06 2003-09-18 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
CA2609953A1 (en) * 2005-05-09 2007-04-12 Foamix Ltd. Saccharide foamable compositions
WO2008022032A2 (en) 2006-08-11 2008-02-21 Solvay Pharmaceuticals, Inc. Topical pharmaceutical compositions comprising calcium-channel blocker and method of using same
KR20090074158A (ko) * 2006-09-01 2009-07-06 모베르그 데르마 아베 디하이드로피리딘 칼슘 길항제를 포함하는 국소성 조성물
WO2008154368A2 (en) * 2007-06-08 2008-12-18 University Of Virginia Patent Foundation Topical poloxamer formulations for enhancing microvascular flow: compositions and uses thereof
JP5072748B2 (ja) * 2007-07-10 2012-11-14 株式会社 メドレックス アムロジピンの安定な液剤とゼリー剤
CN101468001A (zh) * 2007-12-29 2009-07-01 北京瑞康医药技术有限公司 含有氨氯地平系列盐和他汀类药物的治疗组合物
US8686040B2 (en) 2008-03-31 2014-04-01 Rdd Pharma Ltd. Method for treating anal pruritis and other perianal disorders
JP2009256216A (ja) * 2008-04-14 2009-11-05 Towa Yakuhin Kk 溶液状態で安定なアムロジピンベシル酸塩内服用液剤
RU2011111206A (ru) * 2008-10-31 2012-12-10 Моберг Дерма Аб Композиции для местного применения, содержащие комбинацию по меньшей мере двух агентов, усиливающих проникновение
GB0906868D0 (en) * 2009-04-21 2009-06-03 Rabin Bennie Amlodipine salt compositions
JP5960061B2 (ja) 2009-12-18 2016-08-02 エクソドス ライフ サイエンシーズ リミテッド パートナーシップ 末梢血管疾患を治療するための方法および組成物
US10471131B2 (en) * 2012-01-19 2019-11-12 Hybrid Medical, Llc Topical therapeutic formulations
BR112014028610A2 (pt) 2012-05-17 2017-06-27 Contract Pharmaceuticals Ltd formulações de vesícula não iônica de bloqueadores de canal de cálcio
RU2592366C2 (ru) 2013-07-22 2016-07-20 Общество с ограниченной ответственностью "ХИЛИНГ ФАРМ" Фармакологическая композиция для лечения проктологических заболеваний (варианты)
WO2015051336A1 (en) 2013-10-03 2015-04-09 David Wise Compositions and methods for treating pelvic pain and other conditions
WO2016118040A1 (ru) 2015-01-21 2016-07-28 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" Гель, содержащий нифедипин и лидокаина гидрохлорид, его применение и способ приготовления с использованием нанотехнологий
IT201800002413A1 (it) 2018-02-05 2019-08-05 Carmine Antropoli "composizione a base di nifedipina per uso nel trattamento delle ragadi anali e proctalgie"
BR102018008324A2 (pt) 2018-04-25 2019-11-05 Laboratorios Ferring Ltda composição farmacêutica de uso tópico e processo de fabricação de composição farmacêutica de uso tópico
WO2019226542A1 (en) 2018-05-22 2019-11-28 Weinberg Assa Methods for prevention and treatment of pressure ulcers caused by ischemia using contact vasodilators
US11197848B2 (en) 2018-06-01 2021-12-14 Tavanta Therapeutics Hungary Incorporated Topical amlodipine salts for the treatment of anorectal diseases

Also Published As

Publication number Publication date
CA3102228A1 (en) 2019-12-05
US11766428B2 (en) 2023-09-26
CR20200630A (es) 2021-05-26
JP2021526554A (ja) 2021-10-07
WO2019229535A3 (en) 2020-01-30
US20230414591A1 (en) 2023-12-28
US11197848B2 (en) 2021-12-14
SG11202012365QA (en) 2021-01-28
CN112423736A (zh) 2021-02-26
US20220000850A1 (en) 2022-01-06
KR20210023908A (ko) 2021-03-04
WO2019229535A2 (en) 2019-12-05
IL279121B1 (en) 2024-02-01
EP3801460A2 (en) 2021-04-14
IL279121A (en) 2021-01-31
AU2019276832A1 (en) 2021-01-21
BR112020024395A2 (pt) 2021-03-02
MX2020012949A (es) 2021-05-12
US20190365732A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
CL2020002043A1 (es) Métodos y composiciones para la entrega de proteínas terapeuticas.
CY1124834T1 (el) Αναστολεις της αλληλεπιδρασης της μηνινης-mll
CL2018003291A1 (es) Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018).
CY1124432T1 (el) Φαρμακευτικες συνθεσεις που αποτελουν ν-(3,5-διμεθοδυφαινυλ)-ν'-(1-μεθυλαιθυλ)-ν-[3-(1--μεθυλ-1η-πυραζολ-4-υλ)κινοοξαλιν-6-υλ]αιθανο-1,2-διαμινη
CY1119645T1 (el) Τριπεπτιδικοι αναστολεις πρωτεασης εποξειδικης κετονης
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
AR107303A1 (es) Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CL2018002807A1 (es) Métodos de tratamiento de cánceres pediátricos.
CL2020001797A1 (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas.
ECSP21038390A (es) Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr
CR20110608A (es) Derivados de 1h-imidazo-[4,5-c]-quinolinona
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
ECSP21051825A (es) COMPUESTOS Y SU USO PARA EL TRATAMIENTO DE LA DEFICIENCIA DE a1-ANTITRIPSINA
TN2019000033A1 (fr) Agents thérapeutiques pour maladies neurodégénératives
CO2020016480A2 (es) Sales tópicas de amlodipino para el tratamiento de enfermedades anorrectales
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
BR112022008365A2 (pt) Inibidores de cd73
BR112015027399A2 (pt) ANTICORPOS ANTI-IGF-1R COM LIGAÇÃO DE FcRn ABOLIDA E SEU USO NO TRATAMENTO DE ENFERMIDADES VASCULARES OCULARES
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
AR097997A1 (es) Composición farmaceutica de ibuprofeno y tramadol para uso oftálmico
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
CO2019003865A2 (es) Proteína terapéutica
CO2023008676A2 (es) Compuestos polipéptidos modificados con lactama
IT201600081379A1 (it) Composizione farmaceutica per uso nel trattamento delle patologie prostatiche.